DCLA
REGN icon

Douglas C. Lane & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Douglas C. Lane & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-403
Closed -$206K – 244
2015
Q2 		$206K Buy
+403
New +$197K 0.01% 221

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Douglas C. Lane & Associates's REGN Position: Q3 2015 in Review

Douglas C. Lane & Associates sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 403 shares — an estimated $206K sold.

Douglas C. Lane & Associates first reported a position in REGN in Q2 2015 and held it in 1 quarter. The position peaked at $206K in Q2 2015. 562 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Douglas C. Lane & Associates reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Douglas C. Lane & Associates sold 403 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $206K.
  • Douglas C. Lane & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Douglas C. Lane & Associates's Regeneron Pharmaceuticals position peaked at $206K in Q2 2015.
  • 562 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q3 2015, filed 7 Oct 2015.